Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolent Health, Inc.EVH · Entity 5492 | Director | June 01, 2023 | June 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolent Health, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 819,812 |
Last balance in matching sequence
After 2023-06-01 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2023-06-01 · Exercise / conversion · Acquired 19,060 · Balance 838,872 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Row 2 · 2023-06-01 · Exercise / conversion · Acquired 90,940 · Balance 929,812 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Row 3 · 2023-06-01 · Sale · Disposed 9,091 · Balance 920,721 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.63 to $29.62, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Row 4 · 2023-06-01 · Sale · Disposed 9,969 · Balance 910,752 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.83, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Row 5 · 2023-06-01 · Sale · Disposed 41,914 · Balance 868,838 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.60 to $29.59, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Row 6 · 2023-06-01 · Sale · Disposed 49,026 · Balance 819,812 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.86, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. |
| Class A Common Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2025-02-01 | Direct | 0 |
Reported balance
After 2023-06-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-01 · Exercise / conversion · Disposed 19,060 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F8: The Class A Common Stock Options exercised vested on February 1, 2019. |
| Class A Common Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2026-03-01 | Direct | 17,250 |
Reported balance
After 2023-06-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-06-01 · Exercise / conversion · Disposed 90,940 · Balance 17,250 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F9: The Class A Common Stock Options exercised vested on March 1, 2017, March 1, 2018, March 1, 2019, and March 1, 2020. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 66,064 |
Reported balance
Holding disclosure · report date 2023-06-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 66,064 F7: Shares held of record by the Frank Williams Irrevocable Trust. Mr. Williams serves as the Trustee of the Frank Williams Irrevocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.
F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.63 to $29.62, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.83, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.60 to $29.59, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.86, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: Shares held of record by the Frank Williams Irrevocable Trust. Mr. Williams serves as the Trustee of the Frank Williams Irrevocable Trust.
F8: The Class A Common Stock Options exercised vested on February 1, 2019.
F9: The Class A Common Stock Options exercised vested on March 1, 2017, March 1, 2018, March 1, 2019, and March 1, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 3,584 | $23.00 | $82,432.00 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 3,584 | $3.84 | $13,762.56 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 3,584 | $23.00 | $82,432.00 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 29, 2021 Filed Feb 14, 2022 17:16 UTC | Evolent Health, Inc. EVH · Entity 5492 | GiftClass A Common Stock | 66,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000014 · wf-form5_164487696413052.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 66,064 F1 · ownership.nature: On June 29, 2021 66,064 shares were transferred from the Williams 2019 GRAT to the Frank Williams Irrevocable Trust. Read SEC document |
| June 29, 2021 Filed Feb 14, 2022 17:16 UTC | Evolent Health, Inc. EVH · Entity 5492 | GiftClass A Common Stock | 66,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000014 · wf-form5_164487696413052.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.nature: On June 29, 2021 66,064 shares were transferred from the Williams 2019 GRAT to the Frank Williams Irrevocable Trust. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,560 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $19.70 | $197,000.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.461 to $19.9099, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:58 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $19.70 | $197,000.00 |
DisclosureSEC source: 0001628908-21-000092 · wf-form4_162430911080741.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,294 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.53 to $19.91, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 19:41 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000084 · wf-form4_162371407450832.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,294 F1 · security: Represents restricted stock units granted to Mr. Williams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,560 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $19.65 | $196,500.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.41 to $19.82, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $19.81 | $198,100.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $19.90, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628280-21-010735 · wf-form4_162146972771096.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:56 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantLeveraged Restricted Stock Unit · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628908-20-000037 · wf-form4_158335898553669.xml · derivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Class A Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: These LSUs vest on March 2, 2023. F2 · derivative.expiration_date: These LSUs do not expire. F3 · derivative.underlying_shares: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 17:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | PurchaseClass A Common Stock | 35,000 | $6.51 | $227,850.00 |
DisclosureSEC source: 0001628908-19-000075 · wf-form4_157558408386148.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,655 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $ 6.47 to $6.58, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:02 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantLeveraged Restricted Stock Unit · Derivative | 249,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628908-19-000007 · primary_doc.xml · derivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,000 Underlying: Class A Common Stock · 249,000 shares Expires not disclosed F1 · shares: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock. F2 · derivative.exercise_date: These LSUs vest on March 2, 2022. F3 · derivative.expiration_date: These LSUs do not expire. F1 · derivative.underlying_shares: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 16:38 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 3,878 | $24.00 | $93,072.00 |
DisclosureSEC source: 0000950157-18-000921 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 16:37 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 7,956 | $24.00 | $190,944.00 |
DisclosureSEC source: 0000950157-18-000914 · form4.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,235 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 16:37 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 29,953 | $24.02 | $719,471.06 |
DisclosureSEC source: 0000950157-18-000914 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,191 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.15, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 16:25 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 5,545 | $24.00 | $133,080.00 |
DisclosureSEC source: 0001628908-18-000065 · primary_doc.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,144 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-24.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 16:25 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 35,470 | $24.02 | $851,989.40 |
DisclosureSEC source: 0001628908-18-000065 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,689 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.10, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 17:02 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 9,653 | $19.97 | $192,770.41 |
DisclosureSEC source: 0001628908-18-000059 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,159 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighed average. These shares were sold in multiple transactions at prices ranging from $19.60-$20.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:22 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,231 | $21.22 | $217,101.82 |
DisclosureSEC source: 0001628908-18-000054 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.600-$21.575, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 18:08 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 47,314 | $24.00 | $1,135,536.00 |
DisclosureSEC source: 0001628908-18-000053 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:30 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 15,000 | $20.04 | $300,600.00 |
DisclosureSEC source: 0001628908-18-000036 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.65-$20.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 14, 2018 Filed May 16, 2018 16:16 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 15,000 | $19.02 | $285,300.00 |
DisclosureSEC source: 0001628908-18-000032 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.00-$19.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:40 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock Option (right to buy) · Derivative | 227,273 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000003 · primary_doc.xml · derivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,273 Underlying: Class A Common Stock · 227,273 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:40 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 96,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000003 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,357 F1 · security: Represents restricted stock units granted to Mr. Williams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 16:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 16,300 | $23.73 | $386,799.00 |
DisclosureSEC source: 0001628908-17-000039 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,583 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $23.425-$24.100, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 16:56 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 1,250 | $25.27 | $31,587.50 |
DisclosureSEC source: 0001628908-17-000035 · primary_doc.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,883 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.20-$25.50, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 16:56 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 15,050 | $24.72 | $372,036.00 |
DisclosureSEC source: 0001628908-17-000035 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,133 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.35-$25.15, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:45 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 11,800 | $24.36 | $287,448.00 |
DisclosureSEC source: 0001204938-17-000005 · primary_doc.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834,183 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.00-$24.60, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:45 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 4,500 | $23.49 | $105,705.00 |
DisclosureSEC source: 0001204938-17-000005 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,983 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $22.90-$23.85, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 19, 2017 Filed May 23, 2017 18:23 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 114,865 | $24.30 | $2,791,219.50 |
DisclosureSEC source: 0000950157-17-000720 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,483 F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 04, 2017 Filed May 8, 2017 18:20 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 16,300 | $23.55 | $383,865.00 |
DisclosureSEC source: 0001204938-17-000004 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284,943 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $23.15-$23.85, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2017 Filed Apr 10, 2017 16:31 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 16,300 | $22.03 | $359,089.00 |
DisclosureSEC source: 0001204938-17-000003 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,243 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $21.85-$22.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 17:47 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 16,300 | $20.86 | $340,018.00 |
DisclosureSEC source: 0001204938-17-000002 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,317,543 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.55-$21.25, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 17:20 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 16,300 | $20.13 | $328,119.00 |
DisclosureSEC source: 0001204938-17-000001 · primary_doc.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333,843 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.00-$20.275, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 17:20 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 16,300 | $20.16 | $328,608.00 |
DisclosureSEC source: 0001204938-17-000001 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,143 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $20.00-$20.30, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 19:39 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock Option (right to buy) · Derivative | 137,868 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0000950157-17-000201 · form4.xml · derivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,868 Underlying: Class A Common Stock · 137,868 shares Expires 2027-02-01 F3 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2018. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 19:39 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 61,644 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-17-000201 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,366,443 F1 · security: Represents restricted stock units granted to Mr. Williams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2018. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 16:45 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 251,481 | $21.54 | $5,416,900.74 |
DisclosureSEC source: 0000950157-16-002174 · form4.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304,799 F1 · price: The price of $21.54 represents the public offering price of $22.50 per share of Class A Common Stock less the underwriters' discount of $0.96 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.